Servier receives a positive CHMP opinion for Tibsovo® in IDH1- mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients.

Paris, France – 24 February, 2023 – Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Tibsovo ® (ivosidenib tablets) - an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme - for two indications